Atossa Therapeutics, a leading clinical stage biopharmaceutical company focused on addressing unmet needs in oncology, recently announced a significant development in the ongoing RECAST DCIS study. The company disclosed that the first patient has been administered Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, as part of the study. This groundbreaking study aims to evaluate the suitability of long-term active surveillance without surgery for women diagnosed with Ductal Carcinoma In Situ (DCIS) through neoadjuvant endocrine therapy.
DCIS, a non-invasive form of breast cancer, is characterized by the presence of abnormal cells in the milk ducts of the breast. Traditionally, surgical intervention in the form of a lumpectomy or mastectomy has been the go-to treatment option for women diagnosed with DCIS. However, recent research suggests that active surveillance in some cases may be a viable alternative.
The RECAST DCIS study is designed to offer women diagnosed with DCIS a six-month neoadjuvant endocrine therapy using (Z)-endoxifen. By administering this targeted therapy, Atossa Therapeutics aims to evaluate whether it is possible to identify patients who may not require surgical intervention and can instead be managed through active surveillance.
(Z)-endoxifen is a SERM specifically designed to inhibit the estrogen receptor pathway, which is often critical for the growth and proliferation of hormone receptor-positive breast cancer cells. As a targeted therapy, (Z)-endoxifen has the potential to address the specific needs of DCIS patients by selectively modulating estrogen receptors and preventing tumor growth without the need for invasive surgery.
The initiation of patient dosing in the RECAST DCIS study marks a significant milestone for Atossa Therapeutics. By offering a non-invasive treatment option to patients with DCIS, this clinical trial has the potential to revolutionize the management of this condition and improve the quality of life for women diagnosed with it.
The comprehensive study design allows for thorough evaluation of the long-term impact of (Z)-endoxifen treatment in DCIS patients. The primary endpoint is the rate of complete response, defined as the absence of abnormal cells in breast tissue biopsies following neoadjuvant endocrine therapy. Secondary endpoints include imaging response, breast conservation rate, mastectomy-free survival rate, and safety and tolerability of (Z)-endoxifen.
The announcement by Atossa Therapeutics is expected to generate excitement within the medical community and among breast cancer patients. If the study confirms the efficacy of (Z)-endoxifen in managing DCIS without surgery, it may signify a significant breakthrough in the treatment of this condition and potentially spare thousands of women from undergoing unnecessary surgeries.
In conclusion, Atossa Therapeutics’ initiation of patient dosing with (Z)-endoxifen in the ongoing RECAST DCIS study represents a promising development in breast cancer research. By exploring the potential of active surveillance as an alternative to surgery, this study may pave the way for a paradigm shift in the management of DCIS. The results of this clinical trial have the potential to offer valuable insights and provide a foundation for personalized treatment approaches in the future, contributing to improved patient outcomes and quality of life.
Comments